SB020 / Sterna Biologicals - LARVOL DELTA

Unleashing anti-tumor immunity: Targeting the autophagy-related protein VPS34 to enhance STING agonist-based therapy. (PubMed, Autophagy Rep) - "In vivo, treatment with the VPS34 inhibitor SB02024 enhances the positive effects of the STING agonist ADU-S100 in melanoma tumor-bearing mice. Thus, our study suggests that VPS34 inhibitors could be used to enhance STING-based anticancer therapies. CCL5 (C-C motif chemokine 5); CXCL10 (C-X-C motif chemokine 10); IFN (interferon); VPS34 (vacuolar protein sorting 34); cGAS (cyclic GMP-AMP Synthase); STING (stimulator of interferon genes protein); cGAMP (2'3'-cyclic guanosine monophosphate-adenosine monophosphate)."

IO biomarker • Journal • Genito-urinary Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • CCL5 • CGAS • CXCL10 • IFNB1 • STING

Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacy. (PubMed, Mol Oncol) - "These results show that VPS34 inhibition augments the cGAS/STING pathway, leading to greater tumor control through immune-mediated mechanisms. We propose that pharmacological VPS34 inhibition may synergize with emerging therapies targeting the cGAS/STING pathway."

IO biomarker • Journal • Oncology • CGAS • CXCL10 • STING

Synthesis and Preclinical Evaluation of Novel Ga-Labeled (R)-Pyrrolidin-2-yl-boronic Acid-Based PET Tracers for Fibroblast Activation Protein-Targeted Cancer Imaging. (PubMed, Pharmaceuticals (Basel)) - "However, since its tumor uptake was considerably higher than [Ga]Ga-PNT6555, the corresponding tumor-to-organ uptake ratios for [Ga]Ga-SB04028 were also significantly greater than [Ga]Ga-PNT6555. Our data demonstrate that (R)-(((quinoline-4-carbonyl)-d-alanyl)pyrrolidin-2-yl)boronic acid is a promising pharmacophore for the design of FAP-targeted radiopharmaceuticals for cancer imaging and radioligand therapy."

Journal • Preclinical • Oncology • FAP

Genomics and phylogeny of the proposed phylum 'Candidatus Poribacteria' associated with the excavating sponge Thoosa mismalolli. (PubMed, Antonie Van Leeuwenhoek) - "This is the first comparative study that includes MAGs from a non-sponge host (Porites lutea) to elucidate the taxonomy of the poorly known Candidatus phylum in a polyphasic approach. Finally, our study also contributes to the sponge microbiome project by reporting the first MAGs of the proposed phylum 'Candidatus Poribacteria' isolated from the excavating sponge T. mismalolli."

Journal

[VIRTUAL] Inhibition of the autophagy related protein Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy (CIMT 2021) - "Combining Vps34i improved the therapeutic benefit of anti-PD-L1/anti- PD1 in melanoma and CRC and prolonged mice survival. Our study revealed for the first time that targeting Vps34 can turn immune cold tumors into immune hot inflamed tumors, thus enhancing the efficacy of anti- PD-L1/anti-PD-1 blockade."

Colorectal Cancer • Gastrointestinal Cancer • Melanoma • Oncology • Solid Tumor • CD4 • CD8 • CXCL10 • IFNG • STAT1

Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy. (PubMed, Sci Adv) - "Combining Vps34i improved the therapeutic benefit of anti-PD-L1/PD-1 in melanoma and CRC and prolonged mice survival. Our study revealed that targeting Vps34 turns cold into hot inflamed tumors, thus enhancing the efficacy of anti-PD-L1/PD-1 blockade."

Journal • Melanoma • Oncology • Solid Tumor • CCL5 • CD8 • CXCL10

Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib. (PubMed, Cancer Lett) - "Vps34 inhibitor significantly potentiated cytotoxicity of Sunitinib and Erlotinib in MCF-7 and MDA-MB-231 in vitro in monolayer cultures and when grown as multicellular spheroids. Our data suggests that inhibition of autophagy significantly improves sensitivity to Sunitinib and Erlotinib and that Vps34 is a promising therapeutic target for combination strategies in breast cancer."

Journal